These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 21487653)

  • 61. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium.
    Tahir TA; Eeles E; Karapareddy V; Muthuvelu P; Chapple S; Phillips B; Adyemo T; Farewell D; Bisson JI
    J Psychosom Res; 2010 Nov; 69(5):485-90. PubMed ID: 20955868
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa.
    Powers PS; Klabunde M; Kaye W
    Eur Eat Disord Rev; 2012 Jul; 20(4):331-4. PubMed ID: 22535517
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects.
    Watson BJ; Wilson S; Griffin L; Kalk NJ; Taylor LG; Munafò MR; Lingford-Hughes AR; Nutt DJ
    Psychopharmacology (Berl); 2011 Jul; 216(1):121-9. PubMed ID: 21318564
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
    Fernandez HH; Okun MS; Rodriguez RL; Malaty IA; Romrell J; Sun A; Wu SS; Pillarisetty S; Nyathappa A; Eisenschenk S
    Int J Neurosci; 2009; 119(12):2196-205. PubMed ID: 19916848
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
    Ray LA; Bujarski S; Chin PF; Miotto K
    Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).
    Weisler RH; Nolen WA; Neijber A; Hellqvist A; Paulsson B;
    J Clin Psychiatry; 2011 Nov; 72(11):1452-64. PubMed ID: 22054050
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effect of alcohol cue exposure and acute intoxication on inhibitory control processes and ad libitum alcohol consumption.
    Baines L; Field M; Christiansen P; Jones A
    Psychopharmacology (Berl); 2019 Jul; 236(7):2187-2199. PubMed ID: 30919004
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
    Logge WB; Morris RW; Baillie AJ; Haber PS; Morley KC
    Psychopharmacology (Berl); 2021 May; 238(5):1291-1302. PubMed ID: 30788529
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings.
    Verplaetse TL; Pittman BP; Shi JM; Tetrault JM; Coppola S; McKee SA
    Alcohol Clin Exp Res; 2016 Jul; 40(7):1567-76. PubMed ID: 27246567
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
    Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
    Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.
    Farokhnia M; Schwandt ML; Lee MR; Bollinger JW; Farinelli LA; Amodio JP; Sewell L; Lionetti TA; Spero DE; Leggio L
    Transl Psychiatry; 2017 Apr; 7(4):e1108. PubMed ID: 28440812
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: A human laboratory study.
    Khemiri L; Steensland P; Guterstam J; Beck O; Carlsson A; Franck J; Jayaram-Lindström N
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2240-51. PubMed ID: 26482910
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
    Riesenberg RA; Baldytcheva I; Datto C
    Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial.
    Nejtek VA; Avila M; Chen LA; Zielinski T; Djokovic M; Podawiltz A; Kaiser K; Bae S; Rush AJ
    J Clin Psychiatry; 2008 Aug; 69(8):1257-66. PubMed ID: 18681757
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study.
    Lee MR; Tapocik JD; Ghareeb M; Schwandt ML; Dias AA; Le AN; Cobbina E; Farinelli LA; Bouhlal S; Farokhnia M; Heilig M; Akhlaghi F; Leggio L
    Mol Psychiatry; 2020 Feb; 25(2):461-475. PubMed ID: 29728704
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.
    Bowden CL; Grunze H; Mullen J; Brecher M; Paulsson B; Jones M; Vågerö M; Svensson K
    J Clin Psychiatry; 2005 Jan; 66(1):111-21. PubMed ID: 15669897
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.
    Bortnick B; El-Khalili N; Banov M; Adson D; Datto C; Raines S; Earley W; Eriksson H
    J Affect Disord; 2011 Jan; 128(1-2):83-94. PubMed ID: 20691481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.